FGFR3 and neoplasm: Importantly, moderate-to-strong FGFR3 immunostaining was significantly associated with shorter overall patient survival (p < 0.05, log-rank test, Fig. 1f) and shorter time to tumor recurrence (p < 0.01, log-rank test, Fig. 1g).